Related Experiment Video
Updated: May 28, 2026
Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors
Published on: January 20, 2023
Heat Shock Proteins as Targets for Cancer Therapeutics
Aryaman Trikala1, Binghui Shen2, Sharonlin Bhardwaj3
1School of Medicine, California University of Science and Medicine, Colton, CA 92324, USA.
Abstract:
Introduction: Heat shock proteins (HSPs) are stress-responsive molecular chaperones that are frequently dysregulated in cancer and contribute to tumorigenesis, invasion, metastasis, immune interactions, and resistance to therapy. Distinct HSP families, including HSP27, HSP60, HSP70, HSP90, and HSP110, promote malignant progression through complementary effects on apoptosis regulation, mitochondrial function, proteostasis, and stabilization of oncogenic signaling pathways. This makes HSPs attractive therapeutic targets. Their coordinated roles within stress-adaptive chaperone networks further garner interest in targeting multiple HSP families in cancer therapy. Discussion: Preclinical and clinical studies have established multiple HSP families as promising anticancer targets; however, clinical translation of HSP-directed therapies has been challenged by toxicity, compensatory heat shock responses, and resistance mechanisms. Many N-terminal HSP90 inhibitors have shown clinical utility but have also highlighted the need for alternative approaches, including C-terminal inhibition, HSP70-directed therapies, and rational combination strategies targeting compensatory survival pathways. Emerging inhibitors targeting HSP27, HSP60, and HSP110, as well as HSP-based vaccines, further expand therapeutic opportunities across cancer subtypes. Collectively, these approaches highlight the growing therapeutic relevance of disrupting interconnected HSP networks rather than targeting individual chaperones in isolation. Conclusions: Future development of heat shock protein-targeted therapies will require a deeper understanding of HSP-mediated chemoresistance. Clinical trial and drug development approaches may benefit from combination or multi-targeted strategies that simultaneously disrupt multiple components of the heat shock protein network to achieve more durable anticancer responses.
Insights
Heat shock proteins (HSPs) are key cancer targets, but therapies face challenges. Targeting multiple HSPs simultaneously offers a promising strategy for more durable cancer treatment responses.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Heat shock proteins (HSPs) are stress-responsive chaperones implicated in cancer progression, including tumorigenesis, invasion, metastasis, immune evasion, and therapy resistance.
- Multiple HSP families (HSP27, HSP60, HSP70, HSP90, HSP110) support malignant growth by regulating apoptosis, mitochondrial function, proteostasis, and oncogenic signaling.
- The interconnected nature of HSPs within cellular networks makes them attractive targets for comprehensive cancer therapy.
Purpose of the Study:
- To review the role of HSPs in cancer and evaluate the therapeutic potential of targeting these proteins.
- To discuss the challenges and emerging strategies in the clinical translation of HSP-directed cancer therapies.
- To highlight the importance of targeting interconnected HSP networks for improved therapeutic outcomes.
Main Methods:
- Review of preclinical and clinical studies on HSP-targeted cancer therapies.
- Analysis of challenges in HSP-directed drug development, including toxicity and resistance mechanisms.
- Exploration of novel therapeutic strategies, such as C-terminal HSP90 inhibition, HSP70-directed therapies, and multi-targeted approaches.
Main Results:
- Multiple HSP families have demonstrated potential as anticancer targets, with HSP90 inhibitors showing some clinical utility.
- Clinical translation has been hindered by toxicity, compensatory stress responses, and resistance.
- Emerging strategies include targeting other HSP families (HSP27, HSP60, HSP110), HSP-based vaccines, and combination therapies.
Conclusions:
- Disrupting interconnected HSP networks, rather than individual chaperones, is crucial for effective cancer therapy.
- Future HSP-targeted therapies require a deeper understanding of HSP-mediated chemoresistance.
- Combination or multi-targeted strategies that simultaneously inhibit multiple HSP network components are essential for achieving durable anticancer responses.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:26Protein Networks
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
01:26Bacterial Protein Maturation
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...